17 results on '"Stattin P."'
Search Results
2. Long-Term Outcome of Patients Treated for Hydrocele with the Sclerosant Agent Sodium Tetradecyl Sulphate
- Author
-
Stattin, Pär, Karlberg, Lars, and Damber, Jan-Erik
- Abstract
The long-term outcome of 106 patients treated for hydrocele with the sclerosing agent sodium tetradecyl sulphate was examined. In a questionnaire distributed at a mean time of 40 months after therapy 83/86 (96) of the eligible patients responded and 95 of them were satisfied with the treatment and its long term results. The treatment associated pain was evaluated on a visual analogue scale (0-10) the mean pain score was found to be 1.8 and the mean duration of the pain 2.4 days. When all hydroceles were considered the overall success rate was 88. Side-effects were minor apart from two patients (1.9) with diabetes mellitus who had an intense inflammatory reaction necessitating orchidectomy after sclerotherapy.
- Published
- 1996
- Full Text
- View/download PDF
3. Current routines for transrectal ultrasound-guided prostate biopsy: a web-based survey by the Swedish Urology Network.
- Author
-
Carlsson S, Bratt O, Stattin P, and Egevad L
- Subjects
- Anti-Infective Agents therapeutic use, Ciprofloxacin therapeutic use, Endoscopic Ultrasound-Guided Fine Needle Aspiration instrumentation, Endoscopic Ultrasound-Guided Fine Needle Aspiration statistics & numerical data, Humans, Male, Surveys and Questionnaires, Sweden, Trimethoprim, Sulfamethoxazole Drug Combination therapeutic use, Urology, Anesthesia, Local statistics & numerical data, Antibiotic Prophylaxis statistics & numerical data, Endoscopic Ultrasound-Guided Fine Needle Aspiration methods, Practice Patterns, Physicians', Prostatic Neoplasms diagnosis, Specimen Handling methods
- Abstract
Objective: This study aimed to survey current Swedish practices for performing and handling transrectal ultrasound-guided prostate biopsies., Material and Methods: A Swedish Urology Network (SUNe) was organized for the distribution of information, survey studies and research collaborations. A web-based questionnaire was distributed to the members in 2011., Results: In this first SUNe survey, 137 (91%) of the 151 members replied. All used antibiotic prophylaxis (84% ciprofloxacin, 12% trimethoprim-sulfamethoxazole), most commonly (63%) as a single dose of ciprofloxacin. Local anaesthesia was used by 87%. Half of the respondents only used a "side-fire" probe, whereas 17% always used an "end-fire" probe. Most (84%) routinely took 10 or more biopsy cores. About three-quarters started with the right base of the prostate and did not routinely take midline biopsies. More than one-third never or rarely sampled the anterior part of the prostate. There was great variability in how biopsy location was reported, but 71% considered a national standardized coordinate system desirable. Fine-needle aspiration was used occasionally by 39%, in more than 10% of cases by 6% and always by 2%. Most urologists mounted the biopsy cores on paper before fixation (78%), put only one core per jar (75%) and used flat-bottomed jars (70%)., Conclusions: Most routines for handling of prostate biopsies, antibiotic prophylaxis, local anaesthesia and number of cores were uniform. However, there is still a need for standardization of the performance of ultrasound-guided biopsies. Although the method used to specify biopsy location varied greatly, most urologists would prefer a national standardized system.
- Published
- 2012
- Full Text
- View/download PDF
4. Information on pros and cons of prostate-specific antigen testing to men prior to blood draw: a study from the National Prostate Cancer Register (NPCR) of Sweden.
- Author
-
Fridriksson J, Gunseus K, and Stattin P
- Subjects
- Adult, Aged, Aged, 80 and over, Decision Making, Early Detection of Cancer, Humans, Male, Middle Aged, Practice Guidelines as Topic, Surveys and Questionnaires, Informed Consent statistics & numerical data, Patient Education as Topic statistics & numerical data, Prostate-Specific Antigen blood, Prostatic Neoplasms diagnosis
- Abstract
Objective: Recent guidelines on serum testing of prostate-specific antigen (PSA) levels in asymptomatic men emphasize the importance of an informed decision. This study assessed the proportion of men who had received written or oral information on the possible consequences of testing of serum levels of PSA before blood draw., Material and Methods: From the National Prostate Cancer Register (NPCR) in Sweden, 600 men per year were randomly selected out of all men with T1c prostate cancer who were diagnosed in the work-up of a PSA test as a part of health examination in 2006-2008. In a mailed questionnaire these men were asked whether and how they had been informed about the pros and cons of a PSA test prior to blood draw., Results: In total, 1621 out of 1800 men (90.1%) responded to the questionnaire; 39/1563 (2.5%) reported that they had received only written information before testing, 179/1563 (11.5%) had received both oral and written information, 763/1563 (48.8%) had received oral information only, 423/1563 (27.1%) had not received any information and 159/1563 (10.2%) were not aware of that a PSA test had been performed., Conclusions: The proportion of men who had received written information on the pros and cons of a PSA test before blood draw in the setting of a health examination was low. Improved routines for giving information to the patient before a PSA test are warranted.
- Published
- 2012
- Full Text
- View/download PDF
5. Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance.
- Author
-
Josefsson A, Wikström P, Egevad L, Granfors T, Karlberg L, Stattin P, and Bergh A
- Subjects
- Adenocarcinoma blood supply, Adenocarcinoma mortality, Aged, Aged, 80 and over, Antigens, CD metabolism, Cell Proliferation, Disease Progression, Endoglin, Follow-Up Studies, Humans, Ki-67 Antigen metabolism, Male, Middle Aged, Neoplasm Grading, Neovascularization, Pathologic, Prognosis, Prostate-Specific Antigen metabolism, Prostatic Neoplasms blood supply, Prostatic Neoplasms mortality, Receptors, Cell Surface metabolism, Risk Factors, Tissue Array Analysis, Watchful Waiting statistics & numerical data, von Willebrand Factor metabolism, Adenocarcinoma diagnosis, Biomarkers, Tumor metabolism, Prostatic Neoplasms diagnosis
- Abstract
Objective: The aim of this study was to explore whether vascular density and tumour cell proliferation are related to the risk of prostate cancer death in patients managed by watchful waiting., Material and Methods: From a consecutive series of men diagnosed with prostate cancer at transurethral resection in 1975-1990, tissue microarrays (TMAs) were constructed. A majority of men had no metastases at diagnosis and were followed by watchful waiting (n = 295). The TMAs were stained for Ki67, endoglin and factor VIII-related antigen (vWf)., Results: In univariate Cox analyses, increased Ki67 index, endoglin vascular density and vWf vascular density were associated with shorter cancer-specific survival. Ki67 index and endoglin vascular density added independent prognostic information to clinical stage, estimated tumour size and Gleason score (GS) in multivariate Cox analysis. In GS 6 tumours, high Ki67 index and high endoglin vascular density identified patients with poor outcome. After 15 years of follow-up not a single man out of 34 men with low staining for both markers (35% of all GS 6 tumours) had died of prostate cancer, in contrast to 15 prostate cancer deaths among the remaining 63 men with GS 6 tumours (65% cumulative risk of prostate cancer death). vWf vascular density in benign areas was a prognostic marker in GS 6 and 7 tumours., Conclusions: Men with GS 6 tumours with both low Ki67 index and endoglin vascular density staining scores have a low risk of progression. Additional studies are needed to test whether these two markers can be applied to core biopsies to select patients suitable for surveillance.
- Published
- 2012
- Full Text
- View/download PDF
6. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden.
- Author
-
Bratt O, Berglund A, Adolfsson J, Johansson JE, Törnblom M, and Stattin P
- Subjects
- Age Distribution, Aged, Aged, 80 and over, Humans, Incidence, Male, Middle Aged, Neoplasm Staging, Registries, Sweden epidemiology, Mass Screening, Prostate-Specific Antigen blood, Prostatic Neoplasms diagnosis, Prostatic Neoplasms epidemiology
- Abstract
Objective: To investigate the effects of prostate-specific antigen (PSA) testing of men without clinical signs of prostate cancer on the incidence of prostate cancer in Sweden., Material and Methods: Information on the cause of diagnosis, tumour characteristics and primary treatment for patients diagnosed with prostate cancer between January 1999 and December 2007 was extracted from the National Prostate Cancer Register of Sweden. This register includes data for 95% of Swedish prostate cancer cases., Results: The total age-standardized annual incidence of prostate cancer per 100,000 men increased from 187 in 1999 to 233 in 2004, but decreased thereafter to 196 in 2007. The incidence of asymptomatic cases also peaked in 2004 (at 62 per 100,000 men), but varied six-fold between different counties in that year (16-98 per 100,000 men). Asymptomatic cases (n = 17,143) constituted 15% of all new cases in 2000 and 30% in 2007. Almost as many cases were diagnosed in stage T1c in men with symptoms, usually from the lower urinary tract. Together these two groups constituted 29% of all new cases in 2000 and 52% in 2007. It was estimated that at least one-third of all Swedish men aged 50-75 years had a PSA test between 2000 and 2007., Conclusions: Even though screening for prostate cancer is not recommended in Sweden, PSA testing of men without clinical signs of prostate cancer is common. The effects on the Swedish incidence of prostate cancer were similar to those reported from the USA.
- Published
- 2010
- Full Text
- View/download PDF
7. PCBaSe Sweden: a register-based resource for prostate cancer research.
- Author
-
Hagel E, Garmo H, Bill-Axelson A, Bratt O, Johansson JE, Adolfsson J, Lambe M, and Stattin P
- Subjects
- Cause of Death trends, Early Detection of Cancer, Humans, Incidence, Male, Neoplasm Staging, Prostatic Neoplasms diagnosis, Retrospective Studies, Sweden epidemiology, Prostatic Neoplasms epidemiology, SEER Program
- Abstract
Objective. To construct a database for clinical epidemiological prostate cancer research based on linkages between the National Prostate Cancer Register (NPCR) of Sweden, a population-based, nationwide quality database, and other nationwide registries. Material and methods. By use of the individually unique Swedish Personal Identity Number, the NPCR was linked to the Swedish Cancer Registry, the Cause of Death Register, the Prescribed Drug Register, the National Patient Register and the Acute Myocardial Infarction Register, all held at the Centre for Epidemiology at the National Board of Health and Welfare, and the Register of the Total Population, the Longitudinal Integration Database for Health Insurance and Labor Market Studies and the Multi-Generation Register, held at Statistics Sweden, and to the Swedish Hernia Register. Results. Record linkages between the NPCR and the Swedish Cancer Registry, the Cause of Death Register and the Register of the Total Population generated a database, named PCBaSe Sweden, including 80 079 prostate cancer cases, diagnosed between 1 January 1996 and 31 December 2006. Record linkage between PCBaSe Sweden and the Prescribed Drug Register generated 59 721 unique matches and linkage to the Acute Myocardial Infarction Register resulted in 11 459 matches. Conclusion. PCBaSe Sweden is a newly created and unique database with over 80 000 cases of prostate cancer with comprehensive data on inpatient and outpatient care, patterns of use of prescribed drugs and socioeconomic and familial factors. Many topics in clinical prostate cancer epidemiology can be investigated. using PCBaSe Sweden.
- Published
- 2009
- Full Text
- View/download PDF
8. Nationwide population-based study on 30-day mortality after radical prostatectomy in Sweden.
- Author
-
Carlsson S, Adolfsson J, Bratt O, Johansson JE, Ahlstrand C, Holmberg E, Stattin P, and Hugosson J
- Subjects
- Adult, Aged, Cause of Death trends, Follow-Up Studies, Humans, Male, Middle Aged, Postoperative Period, Prostatic Neoplasms surgery, Retrospective Studies, Risk Factors, Survival Rate trends, Sweden epidemiology, Time Factors, Population Surveillance, Prostatectomy mortality, Prostatic Neoplasms mortality
- Abstract
Objective: The incidence of prostate cancer in Sweden is increasing rapidly, as is treatment with curative intent. Radical prostatectomy (RP) is currently commonly performed, either within or outside large high-volume centres. The aim of this study was to assess the 30-day mortality rate after RP in Sweden., Material and Methods: In this nationwide population-based study, all men diagnosed with localized prostate cancer (< or =70 years, clinical stadium T1-2, prostate-specific antigen < 20 ng/ml) who underwent RP in Sweden between 1997 and 2002 were identified through the National Prostate Cancer Register (NPCR). Mortality within 30 days of RP was analysed through linkage between the follow-up study of the NPCR and the Regional Population Registers. The cause of death in the death certificates were compared with data from the hospitals concerned. To validate the results, a record linkage between the Inpatient Register and the National Population Register was also performed., Results: The number of RPs performed increased over time. Among 3700 RPs performed, four deaths occurred during the first 30 days, yielding a 0.11% 30-day mortality rate. These deaths occurred at three different types of hospital and were all probably related to the RP., Conclusion: This study provides further evidence that RP is a procedure with very low perioperative mortality even when performed outside high-volume centres.
- Published
- 2009
- Full Text
- View/download PDF
9. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
- Author
-
Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andrén O, Bill-Axelson A, Bratt O, Damber JE, Hellström K, Hellström M, Holmberg E, Holmberg L, Hugosson J, Johansson JE, Petterson B, Törnblom M, Widmark A, and Stattin P
- Subjects
- Adenocarcinoma pathology, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Humans, Incidence, Infant, Infant, Newborn, Male, Middle Aged, Neoplasm Staging, Prostate-Specific Antigen blood, Prostatic Neoplasms pathology, Registries, Retrospective Studies, Sweden, Adenocarcinoma diagnosis, Adenocarcinoma therapy, Prostatic Neoplasms diagnosis, Prostatic Neoplasms therapy
- Abstract
Objective: The incidence of prostate cancer is rising rapidly in Sweden and there is a need to better understand the pattern of diagnosis, tumor characteristics and treatment., Material and Methods: Between 1996 and 2005, all new cases of adenocarcinoma of the prostate gland were intended to be registered in the National Prostate Cancer Register (NPCR). This register contains information on diagnosing unit, date of diagnosis, cause of diagnosis, tumor grade, tumor stage according to the TNM classification in force, serum prostate-specific antigen (PSA) levels at diagnosis and primary treatment given within the first 6 months after diagnosis., Results: In total, 72,028 patients were registered, comprising >97% of all pertinent incident cases of prostate cancer in the Swedish Cancer Register (SCR). During the study period there was a considerable decrease in median age at the time of diagnosis, a stage migration towards smaller tumors, a decrease in median serum PSA values at diagnosis, a decrease in the age-standardized incidence rate of men diagnosed with distant metastases or with a PSA level of > 100 ng/ml at diagnosis and an increase in the proportion of tumors with Gleason score <6. Relatively large geographical differences in the median age at diagnosis and the age-standardized incidence of cases with category T1c tumors were observed. Treatment with curative intent increased dramatically and treatment patterns varied according to geographical region. In men with localized tumors and a PSA level of <20 ng/ml at diagnosis, expectant treatment was more commonly used in those aged > or =75 years than in those aged <75 years. Also, the pattern of endocrine treatment varied in different parts of Sweden., Conclusions: All changes in the register seen over time are consistent with increased diagnostic activity, especially PSA testing, resulting in an increased number of cases with early disease, predominantly tumors in category T1c. The patterns of diagnosis and treatment of prostate cancer vary considerably in different parts of Sweden. The NPCR continues to be an important source for research, epidemiological surveillance of the incidence, diagnosis and treatment of prostate cancer.
- Published
- 2007
- Full Text
- View/download PDF
10. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival.
- Author
-
Varenhorst E, Garmo H, Holmberg L, Adolfsson J, Damber JE, Hellström M, Hugosson J, Lundgren R, Stattin P, Törnblom M, and Johansson JE
- Subjects
- Age Distribution, Aged, Aged, 80 and over, Follow-Up Studies, Humans, Incidence, Male, Neoplasm Staging, Prognosis, Prospective Studies, Prostatic Neoplasms diagnosis, Prostatic Neoplasms therapy, Survival Rate trends, Sweden epidemiology, Brachytherapy statistics & numerical data, Prostatectomy statistics & numerical data, Prostatic Neoplasms mortality, Registries statistics & numerical data
- Abstract
Objectives: To provide a descriptive review of the establishment of the National Prostate Cancer Register (NPCR) in Sweden, to present clinical characteristics at diagnosis and to calculate the relative survival of different risk groups after 5 years., Material and Methods: Since 1998, data on all newly diagnosed prostate cancers, including TNM classification, grade of malignancy, prostate-specific antigen (PSA) level and treatment, have been prospectively collected. For the 35,223 patients diagnosed between 1998 and 2002, relative survival in different risk groups has been calculated., Results: Between 1998 and 2002, 96% of all prostate cancer cases diagnosed in Sweden were registered in the NPCR. The number of new cases increased from 6137 in 1998 to 7385 in 2002. The age-standardized rate rose in those aged < 70 years, while it was stable, or possibly declining from 1999, in the older age groups. The proportion of T1c tumours increased from 14% to 28% of all recorded cases. The age-adjusted incidence of advanced tumours (M1 or PSA > 100 ng/ml) decreased by 17%. The proportion of patients receiving curative treatment doubled. Patients with N1 or M1 disease or poorly differentiated tumours (G3 or Gleason score 8-10) had a markedly reduced relative 5-year survival rate., Conclusions: It is possible to establish a nationwide prostate cancer register including basic data for assessment of the disease in the whole of Sweden. The introduction of PSA screening has increased the detection of early prostate cancer in younger men and, to a lesser extent, decreased the incidence of advanced disease. The effect of these changes on mortality is obscure but the NPCR in Sweden will serve as an important tool in such evaluation.
- Published
- 2005
- Full Text
- View/download PDF
11. Geographical variation in incidence of prostate cancer in Sweden.
- Author
-
Stattin P, Johansson R, Lodnert R, Andrén O, Bill-Axelsson A, Bratt O, Damber JE, Hellström M, Hugosson J, Lundgren R, Törnblom M, Varenhorst E, and Johansson JE
- Subjects
- Aged, Humans, Incidence, Male, Neoplasm Staging, Prostate-Specific Antigen blood, Prostatic Neoplasms blood, Prostatic Neoplasms pathology, Retrospective Studies, Rural Population, Sweden epidemiology, Urban Population, Prostatic Neoplasms epidemiology
- Abstract
Objective: To investigate the geographical variation in prostate cancer incidence in Sweden, in particular the incidences of screening-detected tumours and curative treatment of prostate cancer., Material and Methods: Data were retrieved from the National Prostate Cancer Register of Sweden for all cases of prostate cancer diagnosed in the year 2000-01. There were a total of 14 376 cases of prostate cancer and the mean total annual age-adjusted incidence was 197/100 000 men. There were 3318 cases in tumour category T1c, i.e. non-palpable tumours diagnosed during work-up for an elevated serum level of prostate-specific antigen, 1006 of which (30%) were asymptomatic and detected at a health check-up., Results: The difference between the counties with the lowest and highest age-adjusted incidences per 100 000 men of total prostate cancer was almost twofold (128 vs 217). The corresponding variation in incidence of category T1c tumours was more than fourfold (13 vs 60); the difference in incidence of T1c tumours detected in asymptomatic men was up to 10-fold (2 vs 20); and there was more than a fourfold variation in incidence of curative treatment between counties (13 vs 67). Measured incidences were mostly highest in urban regions and in counties with university hospitals., Conclusion: There are large geographical variations in prostate cancer incidence and in the frequency of curative treatment for prostate cancer in Sweden and there appear to be large geographical variations in the uptake of prostate cancer screening.
- Published
- 2005
- Full Text
- View/download PDF
12. Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry.
- Author
-
Stattin P, Johansson R, Damber JE, Hellström M, Hugosson J, Lundgren R, Varenhorst E, and Johansson JE
- Subjects
- Age Distribution, Aged, Biomarkers, Tumor analysis, Biomarkers, Tumor blood, Biopsy, Needle, Health Surveys, Humans, Incidence, Male, Middle Aged, Neoplasm Staging, Palpation methods, Prostate-Specific Antigen analysis, Registries, Risk Factors, Sensitivity and Specificity, Sweden epidemiology, Mass Screening methods, Prostate-Specific Antigen blood, Prostatic Neoplasms diagnosis, Prostatic Neoplasms epidemiology
- Abstract
Objective: The large increase in the incidence of prostate cancer is largely due to testing of serum levels of prostate-specific antigen (PSA). Little is known about how PSA testing is used in clinical practice outside of screening programmes. Essentially, PSA can be used in the health check-ups of men without symptoms as a form of non-systematic screening or in the work-up of symptomatic patients. The aim of this study was to investigate the cause of initiating a work-up leading to a diagnosis of prostate cancer, with emphasis on T1c tumours., Material and Methods: Data on the cause of initiation of work-up leading to a diagnosis of prostate cancer were retrieved from the National Prostate Cancer Registry for 6361 incident cases in tumour category T1c and local stages T2, T3 and T4 registered in Sweden in 2000., Results: For 1496 cases in tumour category T1c (non-palpable tumours detected during work-up of elevated PSA), the cause of PSA testing was health check-ups in 32% of cases, work-up of symptoms suspected to emanate from the prostate in 51% and other causes/not reported in 17%. For all stages combined, the cause of initiation of the diagnostic work-up was health check-ups in 18% of cases, symptoms in 68% and other causes/not reported in 14%., Conclusion: Non-systematic screening using PSA testing has been introduced in Sweden. However, prostate cancer is still most commonly diagnosed during the work-up of symptomatic patients.
- Published
- 2003
- Full Text
- View/download PDF
13. MRI of the skeleton in prostate cancer staging.
- Author
-
Rydh A, Lundblad M, Ahlström KR, Tavelin B, and Stattin P
- Subjects
- Adenocarcinoma pathology, Aged, Aged, 80 and over, Biopsy, Needle, Bone Neoplasms pathology, Bone and Bones diagnostic imaging, Cohort Studies, Humans, Male, Middle Aged, Prognosis, Radionuclide Imaging, Retrospective Studies, Sensitivity and Specificity, Adenocarcinoma secondary, Bone Neoplasms secondary, Magnetic Resonance Imaging methods, Neoplasm Staging methods, Prostate-Specific Antigen blood, Prostatic Neoplasms pathology
- Abstract
Objective: To explore the value of MRI in the detection of bone metastases in newly diagnosed prostate cancer., Material and Methods: MRI examinations of the axial skeleton in 76 patients with newly diagnosed prostate cancer were reviewed, and the relation of these findings to the serum level of prostate specific antigen (PSA) was examined., Results: MRI indicated bone metastases in 26/76 patients (34%) in the entire study group, in 4/24 (17%) with serum PSA <20 ng/ml and in 22/52 (42%) with serum PSA >20 ng/ml., Conclusions: These results suggest that MRI is a more sensitive indicator of suspected bone metastases than bone scintigraphy in the low range of serum PSA, but less sensitive in the high range. Further studies of MRI and bone scintigraphy in parallel in patients with serum PSA <20 ng/ml are needed to elucidate their relative value in the staging of patients with prostate cancer.
- Published
- 2003
- Full Text
- View/download PDF
14. Population-based study of prostate-specific antigen testing and prostate cancer detection in clinical practice in northern Sweden.
- Author
-
Pilebro B, Johansson R, Damber L, Damber JE, and Stattin P
- Subjects
- Age Distribution, Aged, Clinical Medicine standards, Clinical Medicine trends, Humans, Incidence, Male, Mass Screening standards, Mass Screening trends, Middle Aged, Neoplasm Staging, Pilot Projects, Prostatic Neoplasms epidemiology, Registries, Risk Assessment, Sensitivity and Specificity, Survival Analysis, Sweden epidemiology, Prostate-Specific Antigen blood, Prostatic Neoplasms diagnosis
- Abstract
Objective: The pattern of prostate-specific antigen (PSA) testing in clinical practice is largely unknown; it may be used either in asymptomatic men or in the work-up of men with urinary or other symptoms. The aim of this study was to investigate the pattern of PSA testing in clinical practice for men diagnosed with stage T1c prostate cancer in a region with no formal screening programme., Material and Methods: Using the Primary Prostate Cancer Register for Northern Sweden, all cases of stage T1c prostate cancer diagnosed between 1992 and 1999 in the city of Umeå were identified. The cause of PSA testing was assessed by examining the medical records. Men were categorized as asymptomatic, having lower urinary tract symptoms (LUTS) or having symptoms other than LUTS. Prospective registration of the cause of PSA testing in the entire region of Northern Sweden started in 2000., Results: We found that in Umeå only 32/213 (15%) cases diagnosed with T1c prostate cancer were asymptomatic at the time of PSA testing, 55% of men had a PSA test as part of a work-up for LUTS and 30% had other symptoms. In 2000, 126 cases of stage T1c prostate cancer were diagnosed in the entire region and 20/126 (16%) of these men were asymptomatic., Conclusions: PSA testing was mostly used as a tool in the work-up of symptomatic patients in Umeå and also in the region of Northern Sweden. Further studies in other populations are needed.
- Published
- 2003
- Full Text
- View/download PDF
15. Circulating insulin-like growth factor-I and benign prostatic hyperplasia--a prospective study.
- Author
-
Stattin P, Kaaks R, Riboli E, Ferrari P, Dechaud H, and Hallmans G
- Subjects
- Humans, Male, Middle Aged, Prostatic Hyperplasia epidemiology, Risk, Insulin-Like Growth Factor I analysis, Prostatic Hyperplasia blood
- Abstract
Objective: The aim of this study was to investigate the role of insulin-like growth factor-I (IGF-I), a strongly mitogenic and anti-apoptotic factor, in the development of benign prostatic hyperplasia (BPH). The bioactivity of IGF-I within tissues depends on circulating levels, as well as on the local production of IGF-I and the presence of IGF-binding proteins (IGFBPs). The IGFBPs regulate the efflux of IGF-I to the extravascular space and the bioavailability of IGF-I within tissues., Material and Methods: Within the Northern Sweden Health and Disease Study, 60 cases of BPH defined by a history of prostate resection were identified, and two controls per case were selected. IGF-I, IGFBP-1, IGFBP-3 and insulin were measured by immuno-radiometric assays in stored plasma samples drawn a mean of 3.2 years before surgery., Results: The risk of BPH increased with increasing quartile levels of IGF-I adjusted for IGFBP-3 (p(trend) = 0.10) up to a relative risk of 2.16 (95% confidence interval 0.83-5.64) for the highest quartile. The risk decreased with increasing levels of IGFBP-1 (p(trend) = 0.10)., Conclusions: Our results suggest that elevated IGF-I bioactivity may stimulate the development of BPH; however, they were not statistically significant and require confirmation from larger studies.
- Published
- 2001
- Full Text
- View/download PDF
16. p53 expression in correlation to clinical outcome in patients with renal cell carcinoma.
- Author
-
Ljungberg B, Bozoky B, Kovacs G, Stattin P, Farrelly E, Nylander K, and Landberg G
- Subjects
- Adult, Aged, Aged, 80 and over, Biopsy, Needle, Carcinoma, Renal Cell genetics, Carcinoma, Renal Cell mortality, Carcinoma, Renal Cell pathology, Female, Humans, Immunohistochemistry, Kidney Neoplasms genetics, Kidney Neoplasms mortality, Kidney Neoplasms pathology, Male, Middle Aged, Multivariate Analysis, Neoplasm Staging, Ploidies, Probability, Prognosis, Proportional Hazards Models, Risk Factors, Sensitivity and Specificity, Statistics, Nonparametric, Survival Rate, Biomarkers, Tumor analysis, Carcinoma, Renal Cell chemistry, Kidney Neoplasms chemistry, Tumor Suppressor Protein p53 analysis
- Abstract
Objective: The aim of this study was to evaluate the role of p53 as prognostic factor in renal cell carcinoma (RCC) and its relation to clinicopathological factors., Material and Methods: The nuclear accumulation of p53 protein was determined by immunohistochemical analysis in RCC specimens from 90 patients and was correlated with clinical stage, grade, DNA ploidy, S-phase fraction and cancer-specific survival., Results: p53 overexpression was observed in 17 of 90 (19%) tumours. There was a significant correlation to stage (p = 0.016) and grade (p = 0.020) but not to DNA ploidy or S-phase. Patients with high p53 immunoreactivity had shorter cancer-specific survival (p = 0.003) than those with normal p53 protein expression. This difference was found in papillary and chromophobe tumour types (p < 0.0001) but not in conventional RCC., Conclusions: In patients with RCC, significant correlations between p53 protein expression and tumour stage, grade and survival time were observed. For patients with chromophobe and papillary tumour types, but not in conventional RCC, p53 immunoreactivity gave prognostic information, suggesting that the prognostic differences in p53 immunoreactivity might be due to disparate genetic abnormalities in the different RCC types.
- Published
- 2001
- Full Text
- View/download PDF
17. Evaluation of prognostic factors in prostate cancer with partial least squares analysis.
- Author
-
Wikström P, Wikström P, Lissbrant IF, Bergh A, Damber JE, and Stattin P
- Subjects
- Humans, Immunohistochemistry, Least-Squares Analysis, Life Expectancy, Male, Prognosis, Prostatic Neoplasms pathology, Prostatic Neoplasms surgery, Survival Analysis, Biomarkers analysis, Prostatic Neoplasms mortality
- Abstract
Objective: This study was carried out to explore the capability of partial least squares (PLS) analysis, a multivariate projection method, in the evaluation of investigative prognostic biomarkers., Material and Methods: Using PLS analysis, survival and life expectancy were prognosticated in 53 patients with prostate cancer treated with transurethral resection. The age of the patient, stage and grade of the tumours, and immunoreactivity in the tumours for p53, Bcl-2, and TGF-beta1 and its receptors type I and type II (TGFbeta-RI and TGFalpha-RII), and markers for proliferation, vascular density, and macrophage density were included as prognostic factors in the analysis., Results: The prognostic impact of the factors, in decreasing order, was tumour grade, proliferation, stage, vascular density, TGFbeta-RI, metastasis, TGF-beta1, and TGFbeta-RII. Macrophage staining, p53, Bcl-2, and patient age did not contribute to the model. The model explained 62% of the total variance in survival, and the standard deviation of error of prediction was 29 months., Conclusions: PLS analysis may become a useful tool for evaluation of putative prognostic factors.
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.